Background and Aim: Liver cirrhosis is characterized by high morbidity and mortality rates. This study was addressed to evaluate the epidemiological and economic impact of cirrhosis on hospitalizations in a large population in Italy. Methods: Epidemiological analysis was performed using hospital discharge sheets of 57,720 hospitalizations due to liver disease from 2006 to 2008, selected from the Veneto regional archive. In a sample of 100 randomly selected hospitalizations, a detailed cost analysis was performed and a comparison was made with sets of patients admitted for heart failure (HF) and chronic obstructive pulmonary disease (COPD). Results: Among patients with cirrhosis, ascites emerged as the most frequent cause of admission, followed by hepatic encephalopathy, hepatocellular carcinoma, and upper gastrointestinal bleeding. Encephalopathy and ascites were the complications with the highest rates of readmission. The detailed cost analysis of hospitalizations revealed that economic expenses in the set of patients admitted for cirrhosis were about 30% higher than those for patients admitted for HF or COPD, mainly due to the longer duration of hospitalization. Conclusions: Cirrhosis has a relevant epidemiological and economic impact on hospitalizations and preventive strategies for its clinical management are warranted.

Keywords:
Liver cirrhosis, Hospitalization, Epidemiology, Healthcare costs
1.
Pinzani M, Macias-Barragan J: Update on the pathophysiology of liver fibrosis. Expert Rev Gastroenterol Hepatol 2010;4:459-472.
2.
Schuppan D, Afdhal NH: Liver cirrhosis. Lancet 2008;371:838-851.
3.
Fabris P, Floreani A, Carlotto A, Giordani MT, et al: Alcohol is an important co-factor for both steatosis and fibrosis in Northern Italian patients with chronic hepatitis C. J Hepatol 2004;41:644-651.
4.
Stroffolini T, Sagnelli E, Mele A, Craxì A, Almasio P: The aetiology of chronic hepatitis in Italy: results from a multicentre national study. Dig Liver Dis 2004;36:829-833.
5.
Farrell GC, Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43(2 suppl 1):S99-S112.
6.
Bolognesi M, Di Pascoli M, Verardo A, Gatta A: Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol 2014;20:2555-2563.
7.
Sacerdoti D, Pesce P, Di Pascoli M, Brocco S, Cecchetto L, Bolognesi M: Arachidonic acid metabolites and endothelial dysfunction of portal hypertension. Prostaglandins Other Lipid Mediat 2015;120:80-90.
8.
Benvegnù L. Gios M, Boccato S, Alberti A: Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004;53:744-749.
9.
D'Amico G, Garcia-Tsao G, Pagliaro L: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.
10.
ISTAT: Salute, Stili di Vita e Fattori di Rischio, 2002.
11.
Scaglione S, Kliethermes S, Cao G, Shoham D, et al: The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol 2015;49:690-696.
12.
World Health Organization (WHO): Health Statistics and Information Systems. Mortality Database, 2005.
13.
Gatta A, Verardo A, Di Pascoli M, Giannini S, Bolognesi M: Hepatic osteodystrophy. Clin Cases Miner Bone Metab 2014;11:185-191.
14.
Neff GW, Duncan CW, Schiff ER: The current economic burden of cirrhosis. Gastroenterol Hepatol (N Y) 2011;7:661-671.
15.
Tapper EB, Catana AM, Sethi N, Mansuri D, et al: Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis. Cancer 2016;122:852-858.
16.
Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD: Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015;61:1860-1869.
17.
Bolognesi M, Verardo A, Di Pascoli M: Peculiar characteristics of portal-hepatic hemodynamics of alcoholic cirrhosis. World J Gastroenterol 2014;20:8005-8010.
18.
Starley BQ, Calcagno CJ, Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820-1832.
19.
Schmidt ML, Barritt AS, Orman ES, Hayashi PH: Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010. Gastroenterology 2015;148:967-977.
20.
Martin NK, Vickerman P, Dore GJ, Grebely J, et al: Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol 2016;65:17-25.
21.
Brown RE, De Cock E, Colin X, Antoñanzas F, Iloeje UH: Hepatitis B management costs in France, Italy, Spain, and the United Kingdom. J Clin Gastroenterol 2004;38(10 suppl 3):S169-S174.
22.
Morando F, Maresio G, Piano S, Fasolato S, et al: How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. J Hepatol 2013;59:257-264.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.